Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2540530 | 0.93 | MAPT (0.49) | MAPTALDH1A1KDM4ECYP3A4ALOX15 | |
| SCHEMBL10567265 | 0.86 | ALDH1A1 (0.47) | MAPTALDH1A1KDM4ECYP3A4ALOX15 | |
| SCHEMBL25427390 | 0.85 | ALDH1A1 (0.53) | MAPTALDH1A1KDM4ECYP3A4ALOX15 | |
| SCHEMBL228990 | 0.85 | ALDH1A1 (0.58) | MAPTALDH1A1KDM4ECYP3A4ALOX15 | |
| SCHEMBL512256 | 0.84 | ALDH1A1 (0.51) | MAPTALDH1A1KDM4ECYP3A4ALOX15 | |
| SCHEMBL31757016 | 0.84 | ALDH1A1 (0.51) | MAPTALDH1A1KDM4ECYP3A4ALOX15 | |
| SCHEMBL29804996 | 0.84 | ALDH1A1 (0.51) | MAPTALDH1A1KDM4ECYP3A4ALOX15 | |
| SCHEMBL5738649 | 0.82 | NPC1 (0.41) | MAPTALDH1A1KDM4EPKMMAPK1 | |
| SCHEMBL24743370 | 0.81 | ALDH1A1 (0.49) | MAPTALDH1A1KDM4ECYP3A4ALOX15 | |
| SCHEMBL30954094 | 0.80 | ALDH1A1 (0.48) | MAPTALDH1A1KDM4ECYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117143097-A | Beta-carbopol compound, preparation method thereof and application of beta-carbopol compound in resisting Alzheimer disease | 中国人民解放军北部战区总医院 | 2023-12-01 | — | — | CN | claimed |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
| WO-2025030163-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-02-06 | — | — | WO | disclosed |
| WO-2024254534-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024249642-A1 | EGFR INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2024-12-05 | — | — | WO | disclosed |
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-07-25 | — | — | US | disclosed |
| CN-117693505-A | Heteroaryl derivative compounds and uses thereof | 沃若诺伊公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4328222-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-02-28 | — | — | EP | disclosed |
| US-20240025874-A1 | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application | Wayshire Biopharm Holding Limited (US) | 2024-01-25 | — | — | US | disclosed |
| CN-117143097-A | Beta-carbopol compound, preparation method thereof and application of beta-carbopol compound in resisting Alzheimer disease | 中国人民解放军北部战区总医院 | 2023-12-01 | — | — | CN | disclosed |
| EP-1539133-B1 | AMINOCYCLOHEXENE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | GLAXO GROUP LTD (GB) | 2006-08-23 | — | — | EP | disclosed |
| US-20060041123-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| US-20060040925-A1 | Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| WO-2006002047-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
| EP-1578743-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-09-28 | — | — | EP | disclosed |
| WO-2005082879-A1 | COUMARIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-09 | — | — | WO | disclosed |
| EP-1549156-A1 | DENATURED CAROB FLOUR (DCF) WITH A LOW CONTENT OF SOLUBLE TANNINS AND SUGARS, MEANT FOR HUMAN CONSUMPTION AND PROCESS TO OBTAIN IT | Investigacion Y Nutricion, S.L. (ES) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004058144-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004014361-A9 | AMINOCYCLOHEXENE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | GLAXO GROUP LTD (GB) | 2004-04-08 | — | — | WO | disclosed |
| WO-2004014150-A1 | DENATURED CAROB FLOUR (DCF) WITH A LOW CONTENT OF SOLUBLE TANNINS AND SUGARS, MEANT FOR HUMAN CONSUMPTION AND PROCESS TO OBTAIN IT | INVESTIGACION Y NUTRICION, S.L. (ES) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | ERBB2, EGFR, ERBB3 | MAPT 3248/4885ALDH1A1 3064/4885KDM4E 3031/4885 |
| US-20240025874-A1 | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SDHA, FH | MAPT 825/4885ALDH1A1 909/4885KDM4E 1478/4885 |
| US-20060041123-A1 | Antibacterial agents | NQO2, NRDC, IFNG | MAPT 4448/4885ALDH1A1 3099/4885KDM4E 4544/4885 |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | MAPT 3496/4885ALDH1A1 1694/4885KDM4E 2811/4885 |
| US-20060040925-A1 | Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity | QARS1, NQO2, AAAS | MAPT 4662/4885ALDH1A1 3233/4885KDM4E 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.